Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 9128 results

  1. Dupilumab for treating chronic spontaneous urticaria inadequately controlled by H1 antihistamines in children 2 to 11 years [GID-TA12472]

    In development Reference number: GID-TA12472 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Satralizumab for treating relapsing myelin oligodendrocyte glycoprotein antibody associated disease [GID-TA12471]

    In development Reference number: GID-TA12471 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Osteoarthritis - naproxcinod [ID417]

    Discontinued Reference number: GID-TAG426

    Technology appraisal guidance
    Discontinued

  4. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued Reference number: GID-TAG427

    Technology appraisal guidance
    Discontinued

  5. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued Reference number: GID-TAG431

    Technology appraisal guidance
    Discontinued

  6. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

    Technology appraisal guidance
    Discontinued

  7. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  8. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  9. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  10. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  11. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  12. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  13. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  14. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  15. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued